CN117750945A - 通过每天一次(qd)吸入施用的他克莫司的干燥粉末制剂 - Google Patents

通过每天一次(qd)吸入施用的他克莫司的干燥粉末制剂 Download PDF

Info

Publication number
CN117750945A
CN117750945A CN202280042706.7A CN202280042706A CN117750945A CN 117750945 A CN117750945 A CN 117750945A CN 202280042706 A CN202280042706 A CN 202280042706A CN 117750945 A CN117750945 A CN 117750945A
Authority
CN
China
Prior art keywords
tacrolimus
dose
certain embodiments
composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280042706.7A
Other languages
English (en)
Chinese (zh)
Inventor
D·J·克里斯顿森
C·S·克雷恩
约翰·J·柯伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TFF Pharmaceuticals Inc
Original Assignee
TFF Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TFF Pharmaceuticals Inc filed Critical TFF Pharmaceuticals Inc
Publication of CN117750945A publication Critical patent/CN117750945A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280042706.7A 2021-05-12 2022-05-12 通过每天一次(qd)吸入施用的他克莫司的干燥粉末制剂 Pending CN117750945A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187774P 2021-05-12 2021-05-12
US63/187,774 2021-05-12
PCT/US2022/028972 WO2022241105A1 (en) 2021-05-12 2022-05-12 Dry powder formulations of tacrolimus for administration by inhalation once daily (qd)

Publications (1)

Publication Number Publication Date
CN117750945A true CN117750945A (zh) 2024-03-22

Family

ID=81928015

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280042706.7A Pending CN117750945A (zh) 2021-05-12 2022-05-12 通过每天一次(qd)吸入施用的他克莫司的干燥粉末制剂

Country Status (7)

Country Link
US (1) US20220362222A1 (https=)
EP (1) EP4337173A1 (https=)
JP (1) JP2024520912A (https=)
CN (1) CN117750945A (https=)
AU (1) AU2022271790A1 (https=)
CA (1) CA3219943A1 (https=)
WO (1) WO2022241105A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118948810A (zh) * 2024-07-26 2024-11-15 四川大学 一种吸入式的mPEG-PLGA/FK506载药纳米颗粒及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
AU2009214443B2 (en) 2008-02-13 2013-10-10 Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
WO2011163600A2 (en) * 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118948810A (zh) * 2024-07-26 2024-11-15 四川大学 一种吸入式的mPEG-PLGA/FK506载药纳米颗粒及其制备方法和用途

Also Published As

Publication number Publication date
AU2022271790A1 (en) 2023-11-23
EP4337173A1 (en) 2024-03-20
WO2022241105A1 (en) 2022-11-17
US20220362222A1 (en) 2022-11-17
CA3219943A1 (en) 2022-11-17
JP2024520912A (ja) 2024-05-27

Similar Documents

Publication Publication Date Title
US6080762A (en) Pulmonary and nasal delivery of raloxifene
JP2020007342A (ja) 頭痛治療用の鼻腔内ｄｈｅ
EP4491180A1 (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof
KR20120131245A (ko) 기관지 감염의 치료 방법
KR20220049526A (ko) 비-진정성 덱스메데토미딘 치료 양생법
JP2019519489A (ja) 肺高血圧症を治療するための乾燥粉末トレプロスチニル
WO2009115235A1 (en) Pde inhibitors for the treatment of pulmonary hypertension
JP2020523286A (ja) 肺障害の治療方法
KR20170003601A (ko) Ｃｏｐｄ의 치료를 위한 티오트로피움 브로마이드, 포르모테롤 및 부데소니드의 조합
US20120213707A1 (en) Riboflavin Based Aerosol and Use as Placebo in Trials
CN117750945A (zh) 通过每天一次(qd)吸入施用的他克莫司的干燥粉末制剂
JPH10500966A (ja) 経口吸入もしくは吹き込みにより投与する為の化合物、及び組成物
JP2024506840A (ja) 化学ガス曝露を処置する方法
KR20230005937A (ko) 바이러스 감염의 치료 또는 예방을 위한 클로파지민 조성물 및 방법
CN116916889A (zh) 用于肺高压领域的吸入式伊马替尼
KR20230116786A (ko) 만성 폐쇄성 폐질환, 천식, 폐렴, 기관지염, 낭포성 섬유증, 폐부종, 간질성 폐 질환, 사르코이드증, 특발성 폐섬유증, 급성 호흡곤란 증후군 및 폐동맥 고혈압을 치료하기 위한 방법 및 조성물
AU2022261974A1 (en) Compositions of interleukin-1 receptor antagonist
CN114144195A (zh) 血管活性肠肽(vip)用于治疗药源性肺炎的用途
WO2026061535A1 (zh) 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途以及肺动脉高压的治疗方法
HK40070179A (en) Vasoactive intestinal peptide (vip) for use in the treatment of drug-induced pneumonitis
KR20240124352A (ko) 흡입용 분말 및 그 제조방법
US20220054509A1 (en) Methods of treatment for disease from coronavirus exposure
CN114129546A (zh) 一种吸入用药物组合物
CN110664819A (zh) 供吸入的齐墩果酸制剂及其制备方法与医药用途
Watts Pulmonary delivery of tacrolimus for lung transplant and asthma therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination